Jennifer Brown, MD, Oncology, Boston, MA, Brigham and Women's Hospital

JenniferRuthBrownMDPhD

Oncology Boston, MA

Hematologic Oncology

Assistant Professor of Medicine, Dana-Farber Cancer Institute

Dr. Brown is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Brown's full profile

Already have an account?

  • Office

    450 Brookline Avenue
    Dana-Farber Cancer Institute
    Boston, MA 02215
    Phone(617) 632-4564
    Fax(617) 582-7909
  • Is this information wrong?

Education & Training

  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2017
  • Brigham and Women's Hospital
    Brigham and Women's HospitalFellowship, Hematology/Oncology, 2001 - 2004
  • Massachusetts General Hospital
    Massachusetts General HospitalResidency, Internal Medicine, 1998 - 2001
  • Harvard Medical School
    Harvard Medical SchoolClass of 1998

Certifications & Licensure

  • MS State Medical License
    MS State Medical License 2017 - 2021
  • MA State Medical License
    MA State Medical License 2000 - 2022
  • American Board of Internal Medicine Hematology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
    Jennifer R. Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
    Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Final Results from the Multicenter, Open-Label, Phase II GIBB Study of Obinutuzumab+Bendamustine in Previously Untreated Patients with Chronic Lymphocytic Leukemia
    Jennifer R Brown, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Cytogenetic and Molecular Marker Associations to Outcomes with Duvelisib and Ofatumumab Treatment in Patients with Relapsed or Refractory CLL/SLL in the DUO Trial 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • A Phase 3 Trial Comparing the Efficacy and Safety of Acalabrutinib in Combination with Venetoclax with or without Obinutuzumab, Compared with InvestigatorÍs Choice of ... 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven) 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Press Mentions

  • Clinical Challenges: Selecting First-Line Therapy in CLL
    Clinical Challenges: Selecting First-Line Therapy in CLLMay 20th, 2019
  • Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate Developments
    Verastem Oncology Announces Fourth Quarter and Full-Year 2018 Financial Results and Corporate DevelopmentsMarch 12th, 2019
  • Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent Progress
    Verastem Oncology Outlines Strategic Priorities for 2019 and Highlights Recent ProgressJanuary 3rd, 2019

Hospital Affiliations